Furthermore, silibinin may modulate immunity by suppressing HIF-1α in colon cancer (CT26) and ovarian clear-cell carcinoma (HAC-2, OVISE, and RMG-1) cells, influencing the tumor immune landscape [878, 898]. Here, HIF1A is linked to neoplasm.